Sinclair Pharma PLC (SPH) Receives Buy Rating from Peel Hunt

Sinclair Pharma PLC (LON:SPH)‘s stock had its “buy” rating reaffirmed by Peel Hunt in a report issued on Tuesday. They presently have a GBX 68 ($0.84) target price on the specialty pharmaceutical company’s stock. Peel Hunt’s price objective suggests a potential upside of 94.29% from the company’s current price.

Analyst Recommendations for Sinclair Pharma PLC (LON:SPH)

Sinclair Pharma PLC (LON:SPH) opened at 35.00 on Tuesday. The company’s 50-day moving average is GBX 31.95 and its 200-day moving average is GBX 30.69. Sinclair Pharma PLC has a 52-week low of GBX 26.00 and a 52-week high of GBX 36.75. The firm’s market capitalization is GBX 173.94 million.

Your IP Address:

About Sinclair Pharma PLC

Sinclair Pharma plc, formerly Sinclair IS Pharma plc, is a United Kingdom-based specialty pharmaceutical company. The Company is engaged in the manufacture and wholesale distribution of dermatological products. Its segments are Country Operations, which include its operations in France, the United Kingdom, Italy, Germany and Spain, and International Operations, under which the Company sells through a local distributor.

This story was originally published by WKRB News ( and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at

Receive News & Ratings for Sinclair Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sinclair Pharma PLC and related companies with's FREE daily email newsletter.


Leave a Reply

© 2006-2017 WKRB News.